. "I, V" . "Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q-MDS (IPSS low and intermediate-1)"@en . . "1"^^ . . "Myelodysplastic syndrome (MDS) with isolated 5q-chromosomal abnormality and less than 5% bone marrow blasts, according to WHO classi\uFB01cation, represents a separate MDS subgroup. Most such patients have distinct clinical and pathological features and \uFB01t into a diagnosis of 5q-syndrome with isolated 5q-deletion, hypo-proliferative anemia, normal or increased platelet count, low bone marrow blasts (BM), dysplastic megakaryocytes and long survival. Among the most common cytogenetic abnormalities identi\uFB01ed in patients with MDS are interstitial deletions involving the long arm of chromosome 5 in frequencies ranging from 14 to 31%. Patients with the isolated 5q-chromosomal abnormality are considered to have very good prognosis and survival often longer than 100 months. We decided to analyze the prognostic impact of thrombocytopenia in patients with isolated 5q- which is considered one of the best prognostic groups. With the spreading use of potent and expensive immuno-modulatory drugs, the proper selection of patients is called for, in particular with regard to the yet unresolved question of AML transformation. We suggest that cytopenia, especially thrombocytopenia at the time of diagnosis, is an important marker for identifying patients with unfavorable prognosis." . "3"^^ . "RIV/00064173:_____/12:43907105" . . . . "RIV/00064173:_____/12:43907105!RIV13-MZ0-00064173" . "Myelodysplastic syndrome (MDS) with isolated 5q-chromosomal abnormality and less than 5% bone marrow blasts, according to WHO classi\uFB01cation, represents a separate MDS subgroup. Most such patients have distinct clinical and pathological features and \uFB01t into a diagnosis of 5q-syndrome with isolated 5q-deletion, hypo-proliferative anemia, normal or increased platelet count, low bone marrow blasts (BM), dysplastic megakaryocytes and long survival. Among the most common cytogenetic abnormalities identi\uFB01ed in patients with MDS are interstitial deletions involving the long arm of chromosome 5 in frequencies ranging from 14 to 31%. Patients with the isolated 5q-chromosomal abnormality are considered to have very good prognosis and survival often longer than 100 months. We decided to analyze the prognostic impact of thrombocytopenia in patients with isolated 5q- which is considered one of the best prognostic groups. With the spreading use of potent and expensive immuno-modulatory drugs, the proper selection of patients is called for, in particular with regard to the yet unresolved question of AML transformation. We suggest that cytopenia, especially thrombocytopenia at the time of diagnosis, is an important marker for identifying patients with unfavorable prognosis."@en . . . . "0145-2126" . "36" . "000310642500003" . "Leukemia Research" . "16"^^ . . "10.1016/j.leukres.2012.08.002" . . "[8EAA39EA0351]" . . "174403" . "12" . "Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q-MDS (IPSS low and intermediate-1)"@en . "impact; myelodysplastic syndromes"@en . . "Jona\u0161ov\u00E1, Anna" . . "\u010Cern\u00E1, Olga" . "Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q-MDS (IPSS low and intermediate-1)" . . "Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q-MDS (IPSS low and intermediate-1)" . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" .